Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06297603 · ClinicalTrials.gov registry record · Phase 3
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
A Phase 3 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT06297603 is a Phase 3 study of Type 2 Diabetes that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 320 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06297603, a Phase 3 study of Type 2 Diabetes, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Retatrutide
Study Locations (20)
California
- Kidney & Hypertension Center - Apple Valley - Apple Valley
- Hope Clinical Research, Inc. - Canoga Park
- Neighborhood Healthcare Institute of Health - Escondido
- EndoTrials Center for Clinical Research - La Mesa
- UCLA South Bay Endocrinology - Torrance
New York
- Albany Medical College, Division of Community Endocrinology - Albany
- NYC Research INC - Long Island City
- Research Foundation of SUNY - University of Buffalo - Williamsville
Florida
- Northeast Research Institute (NERI) - Fleming Island
- Encore Medical Research - Weston - Weston
Alabama
- Nephrology Consultants - Huntsville
Arizona
- Clinical Research Institute of Arizona (CRI) - Sun City West - Sun City West
Georgia
- Orita Clinical Research - Decatur
Idaho
- CARE Institute - Idaho Falls
Kansas
- Cotton O'Neil Diabetes & Endocrinology - Topeka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2026-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06297603
The ClinicalTrials.gov registry entry for NCT06297603 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (71% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06297603 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT06297603 about?
NCT06297603 is a clinical study titled "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)". The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucos...
What is the current status of trial NCT06297603?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2024-03-15. Estimated completion is 2026-11.
What conditions does trial NCT06297603 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT06297603?
The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT06297603?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06297603 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.